The therapeutic activity of the antagonistic antibody against SIRPα was first tested either alone or in combination with the tumor-opsonizing antibody dinutuximab on the above-mentioned GD2-positive neuroblastoma cell lines NMB, LAN-1, and IMR-32 (wild types). The gene discussed is SIRPA; the disease is neoplasm.